Literature DB >> 21684039

Mechanisms underlying altered striatal synaptic plasticity in old A53T-α synuclein overexpressing mice.

Alessandro Tozzi1, Cinzia Costa, Sabrina Siliquini, Michela Tantucci, Barbara Picconi, Alexander Kurz, Suzana Gispert, Georg Auburger, Paolo Calabresi.   

Abstract

The interactions between certain α-synuclein (SNCA) conformations and dopamine (DA) metabolism cause selective DA neuron degeneration in Parkinson's disease (PD). Preclinical research on PD took advantage of increasing studies involving different animal models which express different forms of mutated SNCA. Transgenic animals expressing mutant α-synucleins such as mice transgenic for A53T-SNCA (TG) are considered valuable models to assess specific aspects of the pathogenesis of synucleinopathies and PD. In this study we performed electrophysiological recordings in corticostriatal slice preparations from young TG overexpressing mice, in which extracellular striatal DA levels appeared to be normal, and in old TG mice, characterized by abnormalities in striatal DA signaling and impaired long-term depression (LTD). We report no difference in TG mice from the two groups of age of either the basal membrane properties and synaptic striatal excitability in respect to age-matched wild-type mice. Furthermore, in old TG mice, showing plastic abnormalities and motor symptoms, we investigated the mechanisms at the basis of the altered LTD. In old TG mice LTD could not be restored by treatments with acute application of DA or by subchronic treatment with L-3,4-dihydroxyphenylalanine (L-DOPA). Conversely, the application of the phosphodiesterase inhibitor zaprinast fully restored LTD to normal conditions via the stimulation of a cyclic guanosine monophosphate (GMP)-protein kinase G-dependent intracellular signaling pathway. These results suggest that, in addition to the dopaminergic alterations reported in this genetic model of PD, other signal transduction pathways linked to striatal synaptic plasticity are altered in an age-dependent manner.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21684039     DOI: 10.1016/j.neurobiolaging.2011.05.002

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  19 in total

1.  Alpha-Synuclein Suppresses Retinoic Acid-Induced Neuronal Differentiation by Targeting the Glycogen Synthase Kinase-3β/β-Catenin Signaling Pathway.

Authors:  Sasuk Kim; Juhee Lim; Yeojin Bang; Jisook Moon; Min-Soo Kwon; Jin Tae Hong; Jeha Jeon; Hyemyung Seo; Hyun Jin Choi
Journal:  Mol Neurobiol       Date:  2017-02-11       Impact factor: 5.590

2.  Subthalamic lesion or levodopa treatment rescues giant GABAergic currents of PINK1-deficient striatum.

Authors:  Nathalie Dehorter; Natalia Lozovaya; B Julius Mdzomba; François J Michel; Catherine Lopez; Vera Tsintsadze; Timur Tsintsadze; Michael Klinkenberg; Suzanna Gispert; Georg Auburger; Constance Hammond
Journal:  J Neurosci       Date:  2012-12-12       Impact factor: 6.167

Review 3.  Cerebrospinal fluid biomarkers in Parkinson disease.

Authors:  Lucilla Parnetti; Anna Castrioto; Davide Chiasserini; Emanuele Persichetti; Nicola Tambasco; Omar El-Agnaf; Paolo Calabresi
Journal:  Nat Rev Neurol       Date:  2013-02-19       Impact factor: 42.937

Review 4.  New synaptic and molecular targets for neuroprotection in Parkinson's disease.

Authors:  Paolo Calabresi; Massimiliano Di Filippo; Antongiulio Gallina; Yingfei Wang; Jeannette N Stankowski; Barbara Picconi; Valina L Dawson; Ted M Dawson
Journal:  Mov Disord       Date:  2012-08-23       Impact factor: 10.338

5.  A Genetic Mouse Model of Parkinson's Disease Shows Involuntary Movements and Increased Postsynaptic Sensitivity to Apomorphine.

Authors:  N Brehm; F Bez; T Carlsson; B Kern; S Gispert; G Auburger; M A Cenci
Journal:  Mol Neurobiol       Date:  2014-10-12       Impact factor: 5.590

6.  Modulation of the ASK1-MKK3/6-p38/MAPK signalling pathway mediates sildenafil protection against chemical hypoxia caused by malonate.

Authors:  L Barros-Miñones; L Orejana; B Goñi-Allo; V Suquía; I Hervías; N Aguirre; E Puerta
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

7.  Complexin-1 and Foxp1 Expression Changes Are Novel Brain Effects of Alpha-Synuclein Pathology.

Authors:  Suzana Gispert; Alexander Kurz; Nadine Brehm; Katrin Rau; Michael Walter; Olaf Riess; Georg Auburger
Journal:  Mol Neurobiol       Date:  2014-08-12       Impact factor: 5.590

8.  Age-dependent effects of A53T alpha-synuclein on behavior and dopaminergic function.

Authors:  Adam W Oaks; Maya Frankfurt; David I Finkelstein; Anita Sidhu
Journal:  PLoS One       Date:  2013-04-01       Impact factor: 3.240

9.  Behavioral characterization of A53T mice reveals early and late stage deficits related to Parkinson's disease.

Authors:  Katrina L Paumier; Stacey J Sukoff Rizzo; Zdenek Berger; Yi Chen; Cathleen Gonzales; Edward Kaftan; Li Li; Susan Lotarski; Michael Monaghan; Wei Shen; Polina Stolyar; Dmytro Vasilyev; Margaret Zaleska; Warren D Hirst; John Dunlop
Journal:  PLoS One       Date:  2013-08-01       Impact factor: 3.240

10.  Striatal dopamine transmission is subtly modified in human A53Tα-synuclein overexpressing mice.

Authors:  Nicola J Platt; Suzana Gispert; Georg Auburger; Stephanie J Cragg
Journal:  PLoS One       Date:  2012-05-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.